# Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

> **NCT04023344** · PHASE3 · COMPLETED · sponsor: **Geropharm** · enrollment: 210 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Diabetes Mellitus

## Interventions

- **DRUG:** Humalog Mix25
- **DRUG:** Insulin Lispro Biphasic 25

## Key facts

- **NCT ID:** NCT04023344
- **Lead sponsor:** Geropharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-14
- **Primary completion:** 2019-01-15
- **Final completion:** 2019-04-18
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023344, "Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04023344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*